|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 103.7 SEK | -0.38% |
|
+3.18% | -18.41% |
Calliditas Therapeutics AB (publ) reported earnings results for the fourth quarter ended December 31, 2023. For the fourth quarter, the company reported sales was SEK 451.56 million compared to SEK 429.04 million a year ago. Net loss was SEK 18.37 million compared to SEK 3.68 million a year ago.
Basic loss per share from continuing operations was SEK 0.34 compared to SEK 0.07 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -18.41% | 508M | |
| +5.31% | 70.44B | |
| +10.97% | 8.94B | |
| -16.83% | 4.75B | |
| +43.48% | 4.5B | |
| +3.20% | 3.85B | |
| -21.36% | 2.34B | |
| -29.67% | 2.2B | |
| +8.38% | 1.96B | |
| +3.90% | 1.65B |
CALLIDITAS THERAPEUTICS AB 
